Home
News
Topics
Sectors
Reports
Events
Clusters
Products
WEEKLY
FOCUS
ALPHA
Search
About Us
Sign in
Chemical Industry News, Data & Insights
About Us
Sign in
Home
News
Topics
Sectors
Reports
Events
Clusters
Products
WEEKLY
FOCUS
ALPHA
Products
WEEKLY
FOCUS
ALPHA
Innovation and Product Development news
(page 14)
22 April 2026
Merck and Google Cloud launch $1B agentic AI platform using Gemini Enterprise
Multi-year collaboration embeds AI across R&D, manufacturing, commercial and corporate functions to boost productivity for 75,000 staff, speed drug development and enable predictive analytics.
22 April 2026
LANXESS debuts biocidal and oxidant portfolio at CHEMUK
At CHEMUK (20–21 May, booth J152): Oxone for low‑temp detergents; disinfectant actives; CDP 'Control‑Detect‑Prevent' plant hygiene; Preventol OX; Klarix EXIT
22 April 2026
Johnson & Johnson — IMAAVY sustains disease control >2 years in antibody‑positive gMG
Phase 3 Vivacity-MG3 and OLE: nipocalimab shows >2-year sustained symptom control in antibody-positive gMG, durable MG-ADL/QMG gains, 50% MSE, steroid-sparing, IgG reduction >64%
22 April 2026
Chugai's FJ3 Fujieda API building wins ISPE 2026 Facility of the Year Honorable Mention
Facility enables dual production of macrocyclic‑peptide and small‑molecule APIs with advanced automation, parallel lines, 0.03 µg/m3 containment and global-scale supply.
22 April 2026
Rompetrol Rafinare’s Vega Ploieşti starts 60%‑purity hexane production
Unit optimizations enable higher‑purity hexane suited for oil extraction, adhesives, paints and degreasing; ~150 t/day capacity, boosts extraction yields and shortens processing time.
22 April 2026
Evonik expands biotech drug-substance capacity in Slovakia
€80M expansion adds downstream fermentation for drug‑substance manufacturing, creates ~50 jobs; follows rhamnolipids plant and boosts biotech scale‑up and sustainability.
The right choices in the European chemical industry
Save time with
chemXplore Alpha
Learn more
22 April 2026
RWE and Polarium to market 50 MW / 135 MWh virtual battery via multi‑asset tolling
1,600+ behind-the-meter batteries are aggregated into a cloud-controlled virtual battery via multi-asset tolling, enabling market access and grid stability; target ~300MW/810MWh, 10k+ sites
22 April 2026
Mitsui Chemicals Expands Investment in U.S. PRT Developer Glydways
Investment advances deployment of on-demand PRT: small autonomous EVs platooning on dedicated lanes; demos in US and UAE; investor to supply materials, parts, regulatory and market support in Asia.
21 April 2026
CATL unveils six battery innovations and integrated charge–swap network
Six batteries: Shenxing (10–15C); Qilin 280Wh/kg (1,000km) & Condensed 350Wh/kg (1,500km); Freevoy hybrid 230Wh/kg (600km); Naxtra Na‑ion GWh scale; charge–swap network, 4k stations.
21 April 2026
Nextchem unveils 100% recycled urban transport seat at Milano Design Week using NX Replast™
Collaborating with Italian design, post-consumer plastics are upcycled into high-performance recycled polymer meeting strength, durability and aesthetics, engineered for closed-loop reuse.
21 April 2026
Roche’s fenebrutinib halves RMS relapse rate to ~1 per 17 years
FENhance 1/2: the BTK inhibitor cut MRI lesion activity vs teriflunomide and showed trends to less disability; PPMS trial non‑inferior to ocrelizumab. Safety: similar LFTs; more deaths.
21 April 2026
FDA approves Merck’s IDVYNSO (doravirine/islatravir)
Once-daily, tenofovir-free two-drug regimen approved for virologically suppressed adults; Phase 3 non-inferior to BIC/FTC/TAF. Contraindicated with strong CYP3A inducers or 3TC/FTC; skin reactions.
21 April 2026
Roche's ENSPRYNG cuts MOGAD relapse risk by 68%
Phase III METEOROID met primary endpoint in MOGAD: treatment cut relapses vs placebo, reduced MRI lesions and rescue therapy use, showed consistent safety; data to be filed with regulators
21 April 2026
EBA annual event: Europe shifts to industrial-scale battery execution
Panelists stressed transition from project launches to industrial ramp-up, needing coordinated policy, finance and market measures, new funding tools, and scalable tech to secure competitiveness
21 April 2026
Genentech Enspryng cuts MOGAD relapse risk 68% in Phase III
METEOROID met its primary endpoint: drug delayed first relapse vs placebo, with early response (~8w), lower relapse rate, fewer MRI lesions and rescue tx; safety consistent; filings planned
21 April 2026
LyondellBasell at CHINAPLAS 2026: solutions and value‑chain collaboration
Showcases polymer innovations and value‑chain collaborations for mobility, packaging, healthcare and consumer goods, highlighting recycling projects and partner co‑development.
21 April 2026
Synthos AGRO at ChemSpec Europe 2026
At ChemSpec Europe in Cologne (6-7 May 2026) to present formulation, contract manufacturing and international cooperation expertise. Meet the sales and formulation teams at Hall 7, Stand H51.
21 April 2026
Nextchem unveils 100% recycled urban transport seat using NX Replast™ at Milano Design Week
At Milano Design Week a 100% post‑consumer recycled urban transport seat is showcased, upcycled into a high‑performance, durable product designed for return to recycling.
21 April 2026
GENOX debuts J and X series shredders at CHINAPLAS 2026
Shows J Series pipe shredder for pipes to 2000mm dia/120mm thick with 6m hopper; X Series twin-shaft high-torque shredder for mixed/rigid waste. Offers turnkey recycling systems and global service
21 April 2026
Merck and Eisai: LITESPARK‑012 triplet regimens fail to improve PFS and OS versus KEYTRUDA+LENVIMA in first‑line RCC
Phase 3 LITESPARK‑012 tested pembrolizumab+lenvatinib+belzutifan and a pembrolizumab+quavonlimab+lenvatinib regimen; safety profiles consistent with prior studies; full analysis ongoing.
21 April 2026
Genox debuts J- and X-series shredders at CHINAPLAS 2026
Showcased a high-capacity pipe shredder for >2,000-mm pipes and a low-speed high-torque twin-shaft unit for mixed heavy waste; provides turnkey recycling systems worldwide.
21 April 2026
Siemens expands Industrial Edge for enhanced data and AI integration
Industrial Edge: AI Suite & WinCC Unified GA. Management adds IEC62443 security and air‑gap. Information Hub gets bidirectional sync and ARM support. New machine‑vision and rugged HW partners.
21 April 2026
Arkema at Chinaplas 2026: high-performance materials
Showcases bio-based, recyclable high-performance polymers, additives and advanced materials for mobility, electronics, semiconductors and consumer goods; highlights Asia production expansions.
21 April 2026
LANXESS at IFAT 2026: Filtration for PFAS, Phosphorus, Micropollutants and UPW
IFAT showcase: ion‑exchange resins and adsorbents for regenerable phosphorus removal (Bayoxide E IN 20), PFAS and fluoride (MDS/TP resins), micropollutants (VP OC), and the LewaPlus design tool.
21 April 2026
Croda launches Matrixyl Neolide controlled‑release skincare peptide
Patented encapsulation enables controlled peptide release up to 15 days, visible firming (25% in 2 weeks), microneedling synergy (+31% collagen‑III), 99.8% natural, vegan and lower carbon footprint.
21 April 2026
Statkraft completes Montes de Cierzo repowering with 98% waste recovery
44 ageing turbines replaced by 10 new units; capacity rises from 60 to 90 MW and output to 300 GWh/yr. 14.26 MW (28.51 MWh) batteries added. €5M local co-investment; full repower by 2027.
21 April 2026
LKAB advances Luleå critical‑minerals demonstration plant
Installation underway at demo facility; building complete, commissioning autumn. Malmberget pilot tests the chain. Tech will extract phosphorus and 17 REEs from iron‑ore residues; permits ongoing.
21 April 2026
Axens, IFPEN and JEPLAN validate industrial-scale textile-to-textile polyester recycling
Semi-industrial test processed tens of tons of post-consumer polyester textiles to produce BHET monomer, validating textile-to-textile chemical recycling and enabling circular polyester loops.
21 April 2026
BASF expands HALS and NOR HALS capacity
Boosts supply reliability to meet rising demand; NOR HALS improves UV, heat and chemical resistance for durable agricultural films, enabling multiseason use; AR forms reduce dust for safer handling.
21 April 2026
FDA accepts Roche sBLA for Gazyva/Gazyvaro in systemic lupus erythematosus (SLE)
ALLEGORY phase III: SRI‑4 response 76.7% vs 53.5% (adj diff 23.1%), doubled remission rates, fewer flares and reduced steroid use. FDA decision expected by Dec 2026.
← Previous
Next →
